Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15929434 | 0.94 | HDAC6 (0.42) | HDAC8HDAC6HDAC1HDAC3NPC1 | |
| SCHEMBL15929421 | 0.91 | HDAC3 (0.41) | HDAC8HDAC6HDAC1HDAC3NPC1 | |
| SCHEMBL15929437 | 0.88 | HDAC1 (0.39) | HDAC8HDAC6HDAC1HDAC3NPC1 | |
| SCHEMBL15929460 | 0.82 | BCHE (0.47) | HDAC8HDAC6HDAC1HDAC3LMNA | |
| SCHEMBL15929410 | 0.81 | MAPT (0.46) | LMNAPOLBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL15929441 | 0.79 | TMEM97 (0.36) | HDAC8HDAC6HDAC1HDAC3LMNA | |
| SCHEMBL22236871 | 0.75 | MEN1 (0.38) | HDAC8HDAC6HDAC1HDAC3NPC1 | |
| SCHEMBL15929420 | 0.73 | BCHE (0.48) | HDAC8HDAC6HDAC1HDAC3LMNA | |
| SCHEMBL15929438 | 0.73 | MAPT (0.51) | LMNAPOLBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL15929461 | 0.73 | LOXL2 (0.41) | NPC1LMNAPOLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140219915-A1 | CRYPTATE COMPOUNDS | AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION (AU) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140219915-A1 | CRYPTATE COMPOUNDS | HCCS, SQOR, NQO1 | HDAC8 618/4885HDAC6 613/4885HDAC1 1310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.